FULC
Fulcrum Therapeutics, Inc.Company with tickers: FULC
CIK
1680581
CUSIP
359616109
Shares Outstanding
66,633,321
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $22,186,000 | USD | 2026-03-31 | 10-Q | 2026-04-27 |
| Research & Development | $14,084,000 | USD | 2026-03-31 | 10-Q | 2026-04-27 |
| Operating Income | $-22,186,000 | USD | 2026-03-31 | 10-Q | 2026-04-27 |
| Net Income | $-18,891,000 | USD | 2026-03-31 | 10-Q | 2026-04-27 |
| EPS (Basic) | $-0.25 | USD/shares | 2026-03-31 | 10-Q | 2026-04-27 |
| EPS (Diluted) | $-0.25 | USD/shares | 2026-03-31 | 10-Q | 2026-04-27 |